期刊文献+

塞来昔布防护DA能神经元损伤实验研究 被引量:1

The study on the neuroprotective effects of celecoxib against degeneration of dopaminergic neurons
下载PDF
导出
摘要 目的观察非甾体类抗炎药物-塞来昔布对DA能(DA)神经元损伤的保护作用。方法取新生SD大鼠进行中脑神经细胞的原代培养。采用脂多糖(LPS)制作体外PD炎症模型。实验分为对照组、LPS组、塞来昔布(CB)组。倒置显微镜下观察细胞形态变化,第12小时、第24小时测定中脑细胞培养液上清TNF-α浓度及进行酪氨酸羟化酶(TH)免疫细胞化学检测。结果倒置显微镜下见,12h时LPS组细胞体积略有肿胀,折光性增强,突起变细、缩短,胶质细胞活化。24h时细胞数目明显减少,胞体皱缩,突起明显变细、缩短,部分细胞甚至崩解。对照组、CB组细胞形态变化不明显。12hLPS、CB组中脑神经细胞培养液上清TNF-α浓度与对照组相比均显著升高(P<0.01)。组间比较,LPS组TNF-α浓度比CB组明显升高(P<0.01)。24h时实验两组TNF-α浓度与12h时相比均显著增高(P<0.01)。对照组TH阳性细胞数较多。LPS组部分神经元衰亡,12hTH阳性细胞数与对照组相比显著减少,24h减少更明显(P<0.01)。CB组TH阳性细胞数与对照组相比亦显著减少(P<0.01)。组间比较,LPS组TH阳性细胞数与CB组相比明显减少。结论塞来昔布可减轻LPS对体外培养DA能神经元的炎性损伤作用。 Objective To observe the neuroprotective effects of celecoxib against degeneration of dopaminergic neurons.Methods The primary mesencephalic neural cell deriving from SD newborn rat were cultured.Lipopolysaccharide (LPS) were used to establish inflammator reaction model of PD in vitro.Cultured cells were divided into control group,LPS and CB groups.The concentration of tumor necrosis factor-α(TNF-α) in the culture medium were determined by using ELISA method,and tyrosine hydroxylase immunohistochmisry were performed after cutured for 12 hours and 24 hours. Results The concentration of TNF-α in control group was remarkably lower than in experiment groups at the same time point. ( P 〈0.01).The concentration of TNF-α in LPS group was highest, respectively:in CB group. The amount of TH-positive cells in control group were more than in experimental groups( P 〈0.01). The amount of TH-positive cells in LPS group were lowerest,respectively:in CB group.Conclusion Celecoxib have neuroprotective effect through lessening the degeneration of dopaminergic neurons caused by LPS in vitro.
出处 《中风与神经疾病杂志》 CAS CSCD 北大核心 2009年第2期193-196,共4页 Journal of Apoplexy and Nervous Diseases
基金 辽宁省自然科学基金课题(No.20052072)
关键词 非甾体抗炎药 DA能神经元 炎症反应 Non-steroidal anti-inflammatory drugs Dopaminergic neuron Inflammation
  • 相关文献

参考文献11

  • 1McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease[ J]. Parkinsonism Related Disorders,2004,10 ( suppl 1) :3-7.
  • 2Hirsch EC, Hunot S, Darner P, et al. Glia cells and inflammation in parkinson's disease: a role in neurodengeration [ J ] ? Ann Neurol, 1998,44(supple) 3 : 115-120.
  • 3Shibata H, Katsuki H, Nishiwaki M, et al. Lipopolysaccharide-induced dopaminergic cell death in rat midbain slice culture : role of inducible nitric oxide synthase and protection by indomethacin [ J ]. Neurochem ,2003,86 : 1201-1212.
  • 4Mogi M, Togari A, Tanaka K, et al. Increase in level of tumor necrosis factor in 6- hydroxydopamine lesioned striatum in rats without influence of systemic L-DOPA on the TNT-α induction[ J]. Neurosic Letter, 1999,268 ( 2 ) : 101-104.
  • 5Gao HM, Jiang J, Wilson B, et al. Microglia activation mediated delayed and progressive degeneration of rat nigral dopaminergic neu- rons:relevance to Parkinson 's disease [ J ]. J Neurochem, 2002,81 (6) :1285-1297.
  • 6Maier K, Rau C, Storch MK, et al. Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats [ J ]. Brain Pathol,2004,14:378-387.
  • 7Li G, Cui G. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage [ J ]. The FASEB Journal,2005,19(6) :489-496.
  • 8Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, et al. Neuroprotecrive effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals[ J]. J Neurochem,2001,76 :1895-1904.
  • 9Gayle DA, Ling Z, Tong C, et al. Lipopolysaccaride ( LPS ) -induced dopamine cell loss in culture : roles of tumor necrosis factor-a interleukin-lb,and nitric oxide[J]. Brain Res Dev Brain Res,2002, 133 ( 1 ) :27-35.
  • 10Chen HL,Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease [ J ]. 2004,60 ( 8 ) : 1059- 1064.

同被引文献11

  • 1Dodd S,Berk M.Olanzapine/fluoxetine combinati on for ureatment-resisrant depression:efficacy and clinical utility[J].Expert RevNeurother2008,8(9):1299-1306.
  • 2Muller N,Biedel M,Scheppaeh C,et al.Beneficial antipsychoeffects of celecoxib add-on therapy compared to risperidone aloneschizophrenia[J].Am J Psychiatry,2002,159(6):1029-1034.
  • 3Akhondzadeh S,Tabatabaee M,Amini H,et al.Celecoxib as adjunctive therapy in schizophrenia:a double-blind,randomized and placebocotrolled trial[J].SchizophrRes,2007,90(2):179-185.
  • 4Rapaport MH,Delrahim KK,Bresee CJ,et al.Celecoxib augmentatiof continuously ill patients with schizophrenia[J].Biol Psychiatry,2005,57(12):1594-1596.
  • 5World Health Organization,World Health Report 2001.Mental Health:New Understanding,New Hope[M].Geneva:World Organization,2001:18.
  • 6Murry C,Lopez A.The Global burden of mortality and disability fromdisease,injuries and risk factors in1990 and 2020[M].Cambridge,MA:Haryard University Press,1996:232.
  • 7Amsterdam JD,Homing-rohan M.Treatment algorithms in treatment-resistant depression[J].Psychiatr Clin North Am,1996,19:371-386.
  • 8Lambert G,Johansson M,Agem H,et al.Reduced brain norepi-nephrine and dopanine release in treatment-refractory depressive ill-ness evidenee in support of the catechoiamine hypothesis ofmooddisor[J].J Arch Gen Psychiatry,2005,57:787-793.
  • 9Zalcman S,Green-Johnson JM,Murray L,et al.Cytokine-specific central monoamine alterations induced by interleukin-1,-2 and-6[J].Brain Res,1994,643(1):40-49.
  • 10汪向东.心理卫生评定量表手册[M]增订版[M].北京:中国心理卫生杂志出版社,1999.120-129.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部